

## CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing: BARBARA NOLAN

Signature: Barbara Nolan

Date: October 7, 2004

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Supplemental Information Disclosure Statement</b>	<b>Inventor(s)</b>	<b>James Patrick Dunn, et al.</b>
	<b>Application Number</b>	<b>10/824,731</b>
	<b>Filing Date</b>	<b>April 15, 2004</b>
	<b>Group Art Unit</b>	<b>1614</b>
	<b>Examiner</b>	<b>Not yet assigned</b>
	<b>Attorney Docket No.</b>	<b>R0163B-REG</b>
	<b>Title</b>	<b>SUBSTITUTED QUINAZOLINE COMPOUNDS USEFUL AS P38 KINASE INHIBITORS</b>

Sir:

### Transmittal Letter for Supplemental Information Disclosure Statement


Applicants wish to bring to the attention of the Examiner an International Search Report, dated September 3, 2004 for the PCT application that is a counterpart of the subject application. The attached Information Disclosure Statement is filed in compliance with 37 CFR §1.56, and the documents cited therein may be material to the patentability of the subject patent application.

- [X] Attached with this Transmittal Letter are:
  - (a) A copy of the PCT International Search Report;
  - (b) Form 1449, "List of References Cited," with copies of references (2);
  - (c) Return postcard.
- [X] The Information Disclosure Statement is being submitted before the mailing date of the first Office Action. **Therefore, no fee is due under 37 CFR 1.97(b).**
- [X] Additionally, the undersigned hereby certifies under 37 C.F.R. 1.97(e)(1) that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office on a counterpart foreign application not more than three (3) months prior to the filing of the Information Disclosure Statement. **Therefore, no fee is due.**

[X] Applicants believe that no fees are due. However, should this not be the case, the Commissioner is hereby authorized to charge any additional fees that may be required to Deposit Account No. 18-1700.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,



Grant D. Green  
Reg. No. 31,259  
Attorney for Applicants

Roche Palo Alto  
Patent Law Dept. M/S A2-250  
3431 Hillview Avenue  
Palo Alto, CA 94304  
Direct Phone (650) 855-5311

Date: 10/7/04

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

Attorney Docket Number

R0163B-REG

**Complete if Known**

Application Number	10/824,731
Filing Date	April 15, 2004
First Named Inventor	James Patrick Dunn
Art Unit	1614
Examiner Name	Not yet assigned

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	B1	US-6,476,031	11-05-2002	Scios, Inc.	
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	B2	GB 1,024,908	04-06-1966	Monsanto Chemicals Limited		

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	B3	SHEWCHUK, L., et al, "Binding Mode of the 4-Anilinoquinazoline Class of Protein Kinase Inhibitor: X-ray Crystallographic Studies of 4-Anilinoquinazolines Bound to Cyclin-Dependent Kinase 2 and p38 Kinase", J. Med. Chem, 2000, 43:133-138 (XP002293111, compounds 1-3)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Doc. #126444V1